Morgan Cheatham’s Post

SandboxAQ’s Director of Drug Discovery will present how to combine Molecular Simulations with AI Solutions to Maximize the Probability of Success & Speed

We're excited to join #pharma, #academia, and industry leaders at the 2024 Workshop on Free Energy Methods in Drug Design! Find out where you can hear from SandboxAQ team members at the event: 💡 5/14, 8:55am (CET) - Combining Molecular Simulations with AI Solutions to Maximize the Probability of Success & Speed of Drug Discovery - Andrea Bortolato will discuss building and testing synthetic data using quantum-inspired algorithms paired with #AI 💡 Poster presentation - Unraveling the Puzzle: Linking Functional Activity to Binding Affinities in Complex Biological Systems with Sheenam Khuttan 👉 https://bit.ly/4bgr86o #DrugDiscovery #Alchemy2024

From recent #biotech financings to regulating AI in #medtech, here’s what’s happening in life sciences.

Is your preclinical research facing bottlenecks? Discover how ai4bio’s software sharpens data precision and speeds up research outcomes. 🔍 Featured Products: - AI-driven data analysis tools - Automated Lab Reporting Systems - Predictive Analytics for advanced biomarker discovery Interested in how these solutions can fit into your lab operations? 👉 Reach out to us at info@ai4bio.com for a deep dive into our tailored AI innovations for biology. #AI #Biotechnology #LabAutomation #PreclinicalResearch #MachineLearning #DataAnalysis

It's always a pleasure to be back at TINS: Technology Innovation Studio, Unison's second home, with Suman Lal, Salma B., and the TINS team in #KendalSquare, #Cambridge, "the most innovative square mile on the planet". The Festival of #Genomics and #Biodata last week was excellent. Great to reconnect with Simeón Baker from Genomics England, Matt Newman and the team from DNAnexus, and to make many new contacts at the Broad Institute of MIT and Harvard, Massachusetts Institute of Technology, Harvard Medical School, Memorial Sloan Kettering Cancer Center, Takeda and Johnson & Johnson, not to mention the time with Shwen Gwee, as always! Next Thursday, June 27th, I'm hosting a networking, talk and collaborative brainstorming session on the Value Potential of Integrative #Multiomic Analysis in #BioPharma R&D at TINS: Technology Innovation Studio, CIC (Cambridge Innovation Center). We'll cover: 🧬 The theory behind #multiomic analysis and its value potential in drug development. 🌐 The current landscape, including challenges such as data fragmentation and accessibility. 🤖 The potential role of #FoundationModels and #AI / #machinelearning. 🔮 Envisioning of a future integrative analysis state. 🚀 The necessary technological advancements to achieve the future state. 🔗 How we can bridge critical gaps to achieve this vision. If any of the above are of interest to you, and you're in #Boston or #Cambridge, it would be great to see you there.

$20M seed round for "antibody cages"? The latest Baker Lab spinout is either brilliantly simple or simply brilliant. While everyone's obsessing over AI/ML drug discovery platforms, Archon Biosciences's taken a refreshingly mechanistic approach: stick a dozen antibodies in a protein dodecahedron and watch binding probability soar. It's the kind of solution that makes you think "why didn't we try this before?" But here's what's fascinating - they're not just throwing more antibodies at the problem. They're engineering precise spatial arrangements through computational design. This could be a game-changer for those "undruggable" targets where we understand the biology but can't achieve sufficient target engagement. Feels like we're watching the evolution from "spray and pray" to "cage and engage" in real time. #ProteinDesign #DrugDiscovery #BakerLab

I’ve just made my first stock investment, guided by our cutting-edge work at Gordion! Our Machine Learning platform, which typically helps pharma companies evaluate drug targets and identify likely responders, has an interesting unforeseen benefit: it can predict the outcomes of existing clinical trials. By training on trials with known outcomes, we’ve noticed a clear pattern - successful trials have dramatically high cohort-specific drug target essentiality, while failed ones do not. One standout example is trial NCT06005974, initiated for MEK inhibitor - congratulations Recursion. Inspired by these results, I decided to “put my money where my mouth is” and invest based on our technology predictions. Over the coming months, we’ll be collecting data from the outcomes of these predictions - the closest we can get to bringing our program to the clinic. Stay tuned for updates as we embark on this unexpected journey! 🚀 #InvestmentJourney #MachineLearning #ClinicalTrials #Biotech #AI

Trying to understand the building blocks of life? In the latest episode of the Agents of Tech podcast, we dive into the groundbreaking advancements of AlphaFold, the AI that’s reshaping our understanding of protein structures. Just before John Jumper, Demis Hassabis, and the team at Google DeepMind were awarded the 2024 Nobel Prize in Chemistry, we explored how AlphaFold is accelerating drug discovery and revolutionizing biology. We were joined by Dr. Luke Yates, who highlighted how AI has slashed the time and cost of understanding protein structures—something that used to take months of painstaking lab work. Professor Kyle Rohde discussed how AI is opening new doors in the search for antibiotics to combat diseases like tuberculosis, even predicting compounds that could be life-saving treatments. This episode shines a light on how AI is not just changing the game in medicine, but also offering hope for future breakthroughs in tackling some of the world’s toughest health challenges. Tune in to learn more about the future of science and technology! https://lnkd.in/ebaUyAVk #AIInScience #NobelPrize2024 #AlphaFold #Biotech #DrugDiscovery #ScienceInnovation #TechForGood #ArtificialIntelligence #MedicalBreakthroughs #AgentsOfTech #FutureOfMedicine

News From The Environment + Company News | Nobel Tech in Action | Revolutionizing Our Approach to Drug Discovery 💊 The 2024 Nobel Prize in Chemistry honors breakthroughs in protein folding by David Baker, Demis Hassabis and John Jumper, a technology we also utilize at aimed analytics for advancing drug discovery. This recognition underscores the immense potential of AI in unveiling biological secrets and enhancing healthcare solutions. Highlights: - Nobel-winning AI technology is revolutionizing how we understand and utilize proteins. - aimed analytics harnesses this power, opening new possibilities in medicine. ➡️ Read more in our blog! __________________________________________________________________________________ Infographic: own creation 📷

#ISSCR2024 was full of promise and innovation! ✨ There was a huge amount of research and clinical development on display, especially in the #iPSC space 🧫. We've distilled all of this down into a couple of trends and innovations worth following, here are our two overarching trends to watch: 1. Single Cell Technologies, Molecular Insights, and Predictive AI tools 2. Complex 3D models, and Best Practices on Drug Screening Platforms for Inclusive Therapeutic Developments Did you attend? What were your thoughts? #ISSCR24 #stemcellresearch #celltherapy #sciencemeetsai